Vericel Corp (VCEL) valuation against sector peers: P/E 86.9 (sector median 30.1), P/B 5.7, free-cash-flow yield 2.9%, P/S 6.9.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Metric	VCEL	Sector median	vs median
P/E	86.9	30.1 · n=150	188% above
P/B	5.7	3.9 · n=304	45% above
P/S	6.9	4.2 · n=297	62% above
EV/EBIT	—	25.8 · n=140	—
Free-cash-flow yield	2.9%	1.4% · n=289	103% above
Dividend yield	0.00%	0.00% · n=361	—
Return on equity	7.2%	−3.7% · n=306	—
Return on invested capital	—	0.5% · n=276	—
Gross margin	74.6%	62.4% · n=204	19% above
Net debt / EBITDA	—	1.30 · n=145	—

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Sector peers

The largest companies of the same sector and region.

Instrument	P/E	P/B	EV/EBIT	Free-cash-flow yield	Dividend yield	Smart Score
LLYEli Lilly & Co	48.1	32.9	—	1.5%	0.6%	7/10
JNJJohnson & Johnson	39.8	7.9	—	3.2%	2.0%	8/10
ABBVAbbVie	49.1	—	27.1	3.7%	3.0%	6/10
UNHUnitedHealth	22.8	3.5	17.3	6.3%	2.2%	10/10
MRKMerck	112.5	8.5	—	4.5%	2.4%	9/10
TMOThermo Fisher Scientific	36.6	4.7	34.7	2.9%	0.3%	9/10
AMGNAmgen	28.5	21.3	25.6	4.1%	2.2%	7/10
GILDGilead Sciences	—	15.9	—	6.6%	1.9%	5/10
ABTAbbott	30.2	3.7	28.3	3.9%	2.8%	6/10
PFEPfizer	42.4	1.9	—	6.9%	7.2%	1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Jun 2026 · filed 30 Jul 2026

Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.

Cookie settings